Related references
Note: Only part of the references are listed.Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial
Jorge Cortes et al.
BLOOD (2021)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
Susan Branford et al.
LEUKEMIA (2019)
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
Michael W. Deininger et al.
BLOOD (2016)
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
Wendy T. Parker et al.
BLOOD (2016)
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H. Lipton et al.
LANCET ONCOLOGY (2016)
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
David J. Dorer et al.
LEUKEMIA RESEARCH (2016)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation
Franck E. Nicolini et al.
BLOOD (2009)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
Share Paper
